USE OF DNA PROBES FOR THE DETECTION OF LYME DISEASE

Award Information

Agency: Department of Health and Human Services	Branch: N/A	Award ID: 13606	Program Year/Program: 1990 / SBIR
Agency Tracking Number: 13606	Solicitation Year: N/A	Solicitation Topic Code: N/A	Solicitation Number: N/A

Small Business Information: SERACARE LIFE SCIENCES, INC.
SERACARE LIFE SCIENCES, INC. 1935 AVENIDA DEL ORO, STE F OCEANSIDE, MD 92056 0582
View profile »

Woman-Owned: No

Minority-Owned: No

HUBZone-Owned: No

Phase 1: Fiscal Year: 1990

Title: USE OF DNA PROBES FOR THE DETECTION OF LYME DISEASE

Agency: HHS

Contract: N/A

Award Amount: $49,110.00

Abstract:
THE TREATMENT OF LYME DISEASE COULD BE GREATLY ENHANCED IF IT WERE POSSIBLE TO DETECT THE LYME DISEASE SPIROCHETE DIRECTLY IN BLOOD WITH A HIGHLY SENSITIVE TEST. IT IS PLANNED TO DEVELOP A TEST WHERE A REGION OF THE BORRELIA BURGDORFERI OSPA GENE IS AMPLIFIED USING THE POLYMERASE CHAIN REACTION (PCR) TO OBTAIN THE NECESSARY SENSITIVITY. THE AMPLIFIED PRODUCT WILL BE DETECTED INITIALLY BY SOUTHERNBLOTTING AND EVENTUALLY BY SANDWICH HYBRIDIZATION IN MICROTITER WELLS USING A NONRADIOACTIVE DNA PROBE. IN PHASE I, THE REAGENTS NECESSARY FOR THE PCR AMPLIFICATION OF B. BURGDORFERI DNA WILL BE DEVELOPED, AND, IF POSSIBLE, THE FEASIBILITY OF DETECTING THE SPIROCHETE USING THE PCR AND SOUTHERN BLOTTING WILL BE TESTED. A DIRECT AND SENSITIVE TEST OF THIS TYPE FOR LYME DISEASE SHOULD PERMIT EARLIER DETECTION, BETTER DIAGNOSTIC CONFIRMATION, AND EFFECTIVE MONITORING OF ANTIBIOTIC THERAPY.

Principal Investigator:
Mark M Manak
3012510800

Business Contact:

Small Business Information at Submission:

Biotech Research Laboratories
1600 E Gude Dr Rockville, MD 20850

EIN/Tax ID:

DUNS: N/A

Number of Employees: N/A

Woman-Owned: No

Minority-Owned: No

HUBZone-Owned: No